Pepe G J, Albrecht E D
Department of Physiology, Eastern Virginia Medical School, Norfolk 23501.
Endocrinology. 1991 May;128(5):2395-401. doi: 10.1210/endo-128-5-2395.
We have recently demonstrated that treatment of pregnant baboons with androstenedione (delta 4 A) at midgestation to increase estrogen production induced a pattern of placental cortisol (F) metabolism which was similar to that at term and resulted in de novo F production by the fetus, presumably by activation of the fetal hypothalamic-pituitary-adrenocortical axis. The present study was designed to examine the subcellular events in the fetal adrenal that were apparently stimulated by estrogen-induced alterations in transplacental corticosteroid metabolism. Therefore, we determined the effects of estrogen treatment at midgestation and removal of estrogen action near term on the specific activity of the rate-limiting enzymes delta 5-3 beta-hydroxysteroid dehydrogenase (3 beta HSD) and 17-hydroxylase-17,20-lyase (17 alpha-OHase). Fetal adrenals were obtained on day 100 (n = 11) or day 165 (n = 11) of gestation (term = day 184) from untreated animals, on day 100 from animals receiving delta 4 A daily between days 70-100 (n = 9) to increase placental estrogen production, and on day 165 from baboons treated daily between days 130-164 with antiestrogen ethamoxytriphetol (MER-25; n = 7). The activity of 17 alpha-OHase was determined by incubating adrenal microsomes (105,000 x g) with [3H] progesterone, NAD+, and NADH in phosphate buffer. The radiolabeled products 17-hydroxyprogesterone, delta 4 A, and testosterone were purified, and enzyme activity expressed as picograms of product per min/mg tissue. The activity of 3 beta HSD was determined by incubating adrenal microsomes with [3H]pregnenolone and NAD+ in phosphate buffer. The radiolabeled progesterone product was purified, and enzyme activity was expressed as nanograms per min/mg tissue. Treatment with delta 4 A increased estrogen concentration at midgestation 3-fold to levels comparable to those measured near term. Although fetal adrenal weight was greater at term than at midgestation (p less than 0.05), weight was not increased by delta 4 A treatment. The specific activity (mean +/- SE) of fetal adrenal 17 alpha-OHase at midgestation (181 +/- 29) was increased (P less than 0.05) 3-fold by treatment with delta 4 A to levels (591 +/- 105) comparable to those in adrenal microsomes prepared from untreated animals near term (816 +/- 130). Enzyme activity in adrenals of MER-25-treated baboons was 40%, but not significantly lower than that in term controls.(ABSTRACT TRUNCATED AT 400 WORDS)
我们最近证明,在妊娠中期用雄烯二酮(Δ4A)治疗怀孕的狒狒以增加雌激素的产生,会诱导出一种胎盘皮质醇(F)代谢模式,该模式与足月时相似,并导致胎儿从头产生F,推测是通过激活胎儿下丘脑 - 垂体 - 肾上腺皮质轴实现的。本研究旨在检查胎儿肾上腺中的亚细胞事件,这些事件显然受到雌激素诱导的经胎盘皮质类固醇代谢改变的刺激。因此,我们确定了妊娠中期雌激素治疗以及在接近足月时去除雌激素作用对限速酶Δ5 - 3β - 羟类固醇脱氢酶(3βHSD)和17 - 羟化酶 - 17,20 - 裂解酶(17α - OHase)比活性的影响。在妊娠第100天(n = 11)或第165天(n = 11)(足月为第184天)从未经治疗的动物获取胎儿肾上腺,在第100天从在第70 - 100天期间每天接受Δ4A以增加胎盘雌激素产生的动物获取(n = 9),并在第165天从在第130 - 164天期间每天用抗雌激素乙氧三苯氧胺(MER - 25;n = 7)治疗的狒狒获取。通过在磷酸盐缓冲液中用[3H]孕酮、NAD + 和NADH孵育肾上腺微粒体(105,000×g)来测定17α - OHase的活性。纯化放射性标记产物17 - 羟孕酮、Δ4A和睾酮,酶活性以每分钟每毫克组织产生产物的皮克数表示。通过在磷酸盐缓冲液中用[3H]孕烯醇酮和NAD + 孵育肾上腺微粒体来测定3βHSD的活性。纯化放射性标记的孕酮产物,酶活性以每分钟每毫克组织的纳克数表示。用Δ4A治疗使妊娠中期的雌激素浓度增加了3倍,达到与接近足月时测量的水平相当。尽管足月时胎儿肾上腺重量大于妊娠中期(p < 0.05),但Δ4A治疗并未增加其重量。妊娠中期胎儿肾上腺17α - OHase的比活性(平均值±标准误)(181±29)通过用Δ4A治疗增加了3倍(P < 0.05),达到与从未经治疗的动物接近足月时制备的肾上腺微粒体中的水平(591±105)相当(816±130)。MER - 25治疗的狒狒肾上腺中的酶活性为40%,但不显著低于足月对照组。(摘要截断于400字)